found in breast tumour trials that inhibiting VEGFR‐2 could ‘normalise’ the tumour vasculature, enhancing the administration of tiny nanodrugs, while larger nanoparticles have difficulty penetrating the tumour.214. Here, KDR is linked to neoplasm.